Hedge funds specializing in biotech finally caught a break this summer, courtesy of a little-watched French drug developer, The Wall Street Journal reported on Saturday.

Paris-based Abivax (NASDAQ:ABVX) (OTCPK:AAVXF), which had been valued at roughly $500 million earlier